Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
535.48(c) 537.78(c) 548.2(c) 544.1(c) 515.56(c) Last
940 229 620 561 828 582 901 677 1 431 201 Volume
-1.25% +0.43% +1.94% -0.75% -5.25% Change
More quotes
Financials (USD)
Sales 2020 8 494 M - -
Net income 2020 3 172 M - -
Net cash position 2020 5 458 M - -
P/E ratio 2020 19,4x
Yield 2020 -
Sales 2021 10 854 M - -
Net income 2021 3 923 M - -
Net cash position 2021 9 306 M - -
P/E ratio 2021 14,2x
Yield 2021 -
Capitalization 54 415 M 54 415 M -
EV / Sales 2020 5,76x
EV / Sales 2021 4,16x
Nbr of Employees 8 314
Free-Float 83,1%
More Financials
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (61.5%); - supply of collaborative services (33.3%): working with Sanofi (54.5% of sales) and Bayer (45.5%); - sales of technology licenses (5.2%). The group also provides subcontracting... 
More about the company
Notations Surperformance© of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
All news about REGENERON PHARMACEUTICALS
03:20pCOVID SCIENCE-Drugs, vaccines less effective vs new virus variants; antibody ..
RE
10:14aREGENERON PHARMACEUTICALS : Credit Suisse Adjusts Regeneron's Price Target to $7..
MT
08:27aRegeneron Says Study Confirmed REGEN-COV Neutralizes UK, South Africa COVID-1..
MT
07:52aREGENERON PHARMACEUTICALS : Reports Positive Interim Data with REGEN-COV Antibod..
AQ
07:50aREGENERON : REGEN-COV Is Active Against U.K., South Africa SARS-CoV-2 Variants
DJ
07:01aREGENERON PHARMACEUTICALS : REGEN-COV™ Antibody Cocktail Is Active Against..
PR
01/26REGENERON PHARMACEUTICALS : Antibody Drug Temporarily Protects Against Covid-19,..
DJ
01/26REGENERON PHARMACEUTICALS : Releases Positive Preliminary Results for Regen-Cov ..
MT
01/26REGENERON : Interim Data Positive With REGEN-COV as Passive Vaccine to Prevent C..
DJ
01/26ROCHE : Partner Regeneron Says Antibody Cocktail Effective As Passive Vaccine Ag..
MT
01/25REGENERON PHARMACEUTICALS : BMO Capital Upgrades Regeneron Pharmaceuticals to Ou..
MT
01/25Germany Buys 200,000 Doses Of Regeneron Pharmaceuticals' COVID-19 Drug For $4..
MT
01/21REGENERON PHARMACEUTICALS : Forty of the Nation's Most Talented Young Scientists..
PR
01/21REGENERON PHARMACEUTICALS : Forty of the Nation's Most Talented Young Scientists..
PR
01/21Lilly Antibody Drug Prevents Covid-19 in Nursing Homes, Study Finds
DJ
More news
News in other languages on REGENERON PHARMACEUTICALS
01/26WALL STREET STOCK EXCHANGE : USA-Les valeurs à suivre à Wall Street
01/26WALL STREET STOCK EXCHANGE : USA-Les valeurs à suivre à Wall Street (actualisé)
01/26COVID : Regeneron, partenaire de Roche, obtient des résultats sur un traitement
01/25Apple, LVMH et Tesla au (copieux) menu de la semaine
01/24Spahn kauft Antikörper-Medikamente - Zuspruch von Gesundheitsexperten
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 653,69 $
Last Close Price 544,10 $
Spread / Highest target 45,7%
Spread / Average Target 20,1%
Spread / Lowest Target -8,11%
EPS Revisions
Managers and Directors
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Patrice Gilooly Senior VP-Quality Assurance & Operations
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS12.62%57 427
GILEAD SCIENCES, INC.14.49%83 610
WUXI APPTEC CO., LTD.36.65%64 891
VERTEX PHARMACEUTICALS0.55%61 795
BEIGENE, LTD.38.68%32 675
GENMAB A/S5.56%27 803